The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors.
 
Haruo Iguchi
Honoraria - Lilly; Nihon Medi-Physics; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - AstraZeneca
 
Naoyuki Nogami
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Nippon Kayaku; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca; Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Roche Pharma AG; Taiho Pharmaceutical
Research Funding - AstraZeneca
 
Toshihiko Matsumoto
Research Funding - AstraZeneca
 
Kenji Tamura
Research Funding - AstraZeneca
 
Noboru Yamamoto
Research Funding - AstraZeneca
 
Akihiko Shimomura
Research Funding - AstraZeneca
 
Yuji Hoshino
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yoshiko Michibata
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Masahiro Nii
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yutaka Fujiwara
Research Funding - AstraZeneca